» Articles » PMID: 8589692

Molecular Analysis of De Novo Germline Mutations in the Von Hippel-Lindau Disease Gene

Overview
Journal Hum Mol Genet
Date 1995 Nov 1
PMID 8589692
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

VHL disease is a dominantly inherited familial cancer syndrome with variable expression and age-dependent penetrance. The diagnosis of isolated cases is often delayed compared with familial cases, and estimates of the new mutation rate have varied more than 20-fold. To investigate the frequency and origin of de novo VHL gene mutations we have analysed: (i) families with identical mutations to determine if there is a common haplotype, and (ii) apparent new mutation cases to determine whether the clinical diagnosis of such cases is reliable and to define the parental origin of de novo VHL gene mutations. Haplotyping of 12 VHL mutations occurring in two or more families (total 42 kindreds) revealed that for most mutations there was no evidence of a founder effect. A marked bias for a paternal origin of new mutations has been reported in other familial cancer syndromes such as neurofibromatosis type 1 (NF1), multiple endocrine neoplasia (MEN) 2B and bilateral retinoblastoma, but it is unclear whether this bias results from a greater susceptibility for mutagenesis during male gametogenesis because of the larger number of cell divisions compared with that in oogenesis, or from genomic imprinting effects. Analysis of 13 de novo VHL mutations in which the parent of origin could be established, showed no evidence for a bias for a paternal origin (seven paternal, six maternal), and differed significantly from that reported in NF1, MEN2B and bilateral retinoblastoma. This result demonstrates that an increased susceptibility to paternal allele mutation is not a universal finding in autosomal genetic diseases and that the origin of new mutations may be influenced by both genomic imprinting effects and the increased number of cell divisions in spermatogenesis compared with oogenesis.

Citing Articles

Pathogenicity of germline VHL variants is associated with renal cell carcinoma size in von Hippel-Lindau disease.

Mori G, Fagundes G, Santana L, Freitas-Castro F, Afonso A, Lourenco Jr D Arch Endocrinol Metab. 2025; 69(1):e240354.

PMID: 39945572 PMC: 11834860. DOI: 10.20945/2359-4292-2024-0354.


Genotype-phenotype correlation of ocular von Hippel-Lindau disease in Koreans.

Hwang S, Kang S, Kim J, Kim S PLoS One. 2024; 19(10):e0311665.

PMID: 39374255 PMC: 11458008. DOI: 10.1371/journal.pone.0311665.


Von Hippel-Lindau Disease (VHL): Characteristic Lesions with Classic Imaging Findings.

Bajaj S, Gandhi D, Nayar D, Serhal A J Kidney Cancer VHL. 2023; 10(3):23-31.

PMID: 37555195 PMC: 10404985. DOI: 10.15586/jkcvhl.v10i3.293.


Comprehensive characterization and building of National Registry of von Hippel-Lindau disease in Brazil.

Dallagnol T, Cas E, Ramos Junior O, Casali-da-Rocha J Mol Genet Genomic Med. 2023; 11(4):e2136.

PMID: 36625343 PMC: 10094063. DOI: 10.1002/mgg3.2136.


VHL Ser65 mutations enhance HIF2α signaling and promote epithelial-mesenchymal transition of renal cancer cells.

Ma X, Tan Z, Zhang Q, Ma K, Xiao J, Wang X Cell Biosci. 2022; 12(1):52.

PMID: 35505422 PMC: 9066845. DOI: 10.1186/s13578-022-00790-x.